WALTHAM, Mass.--(BUSINESS WIRE)--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and year ending December 31, 2007; summarized recent clinical and corporate progress; and provided financial and milestone guidance for 2008.
